Through research in the Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic is leading scientific advances in multiple sclerosis treatment.
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...
In this research project, investigators in the Mayo Clinic Ovarian Cancer SPORE are exploring natural killer (NK) cells as an adoptive cellular therapy for cancer.